Merck recalls cholesterol drug Liptruzet (Update)

January 14, 2014 by Dennis Thompson, Healthday Reporter
Merck recalls cholesterol drug liptruzet
Packaging problem could allow air, moisture to affect drug's effectiveness, company says.

(HealthDay)—Packaging defects have prompted a recall of a combination cholesterol drug called Liptruzet, produced by Merck & Co., temporarily affecting the entire U.S. stock.

Merck said the foil pouches holding Liptruzet pills could allow air and moisture inside, potentially decreasing the drug's effectiveness.

The recall covers all four dose strengths and every batch that's gone out since Liptruzet hit the market in May.

Liptruzet combines two medications that work together to reduce "bad" cholesterol levels:

  • Atorvastatin, the generic version of the widely used cholesterol medication Lipitor, which reduces the body's natural cholesterol production, and
  • Zetia (ezetimibe), a Merck-produced drug that decreases the amount of cholesterol absorbed from food.

Cardiologists expect no health problems to result from the recall, in part because both atorvastatin and Zetia will remain available separately.

"Patients are not going to be in any harm's way just going on atorvastatin until this packaging issue gets corrected," said Dr. Kevin Marzo, chief of cardiology at Winthrop-University Hospital in Mineola, N.Y.

Marzo added that since the drug has been out for just a matter of months, it's unlikely that doctors have been prescribing it widely.

If a doctor feels a patient needs the combination treatment, then the doctor can prescribe both drugs individually and the patient can take two pills, said Dr. Deepak Bhatt, executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center, in Boston.

Patients can continue to take any Liptruzet they already have on hand, according to Merck, and should talk with their doctor before they quit taking it.

Bhatt said the real risk of this recall is that patients will hear about it and stop taking their cholesterol medication altogether.

"It should be relatively simple and even cheaper to substitute atorvastatin," Bhatt said. "Bottom line, this is something that can be addressed in a relatively straightforward way. The key is not to say, 'Well, I don't have to take anything in its place.'"

Liptruzet and Zetia each cost more than $5.50 per pill, while atorvastatin costs about a quarter per pill.

Merck said it plans to get Liptruzet back on the market as soon as possible.

Explore further: Merck: FDA wants more studies of insomnia drug

More information: For more on Liptruzet, visit RxList.

Related Stories

Merck: FDA wants more studies of insomnia drug

July 1, 2013

Drugmaker Merck & Co. says federal regulators have ruled that they won't approve high doses of its experimental insomnia medication because of concerns about their safety.

Merck says FDA reviewing its ragweed allergy therapy

May 8, 2013

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.